Loss of exclusivity of ceftazidime/avibactam in low- and middle-income countries: a test for antibiotic stewardship practice

Ceftazidime/avibactam is a last-line antibiotic, to be used as a targeted therapy for certain carbapenem-resistant Gram-negative infections and not to be used as an empirical therapy or as a carbapenem-sparing therapy. After a span of 5 years, the antibiotic recently lost its exclusivity and become...

Descripción completa

Detalles Bibliográficos
Autores principales: Veeraraghavan, Balaji, Bakthavatchalam, Yamuna Devi, Sahni, Rani Diana, Malhotra, Shilpi, Bansal, Nitin, Walia, Kamini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442963/
https://www.ncbi.nlm.nih.gov/pubmed/37614349
http://dx.doi.org/10.1016/j.lansea.2023.100225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442963/
https://www.ncbi.nlm.nih.gov/pubmed/37614349
http://dx.doi.org/10.1016/j.lansea.2023.100225

Ejemplares similares